Patent application EP16152445A (EP), filed 2016-01-22
Publication number: EP3195878A1
Title: BACTERIAL GHOSTS FOR THE TREATMENT OF CANCER
Abstract: [0001]    The present invention relates to a composition comprising Bacterial Ghosts, optionally an active agent, and a pharmaceutically acceptable carrier and/or excipient for use in the treatment of cancer.
IPC codes: A61K  31/   282            A I
A61K  31/  7028            A I
A61K  31/   704            A I
A61K  39/    00            A I
A61K  39/   108            A I
A61P  35/    00            A I
A61P  35/    04            A I
Claims: number: 1
text: Composition comprising
number: 2
text: Composition comprising, in particular consisting of
number: 3
text: Composition comprising, in particular consisting of
number: 4
text: The composition for use according to claim 3, wherein the active agent is a chemotherapeutic drug, for example doxorubicin, oxaliplatin, resveratrol, epirubicin, idarubicin, mitoxantrone, cyclophosphamide, maphosphamide, bortezomib or bleomycin.
number: 5
text: The composition for use according to claim 3, wherein the active agent is a chemotherapeutic drug, preferably a platinum-based chemotherapeutic drug, in particular oxaliplatin.
number: 6
text: The composition for use according to any one of claims 3 to 5, wherein the Bacterial Ghosts are mixed or loaded with the active agent, preferably wherein the active agent is immobilized within the Bacterial Ghosts.
number: 7
text: The composition for use according to any one of the preceding claims, wherein the composition is administered topically, intradermally, subcutaneously, orally, rectally, vaginally, intraperitoneally, intratumorally, peritumorally, and/or by intravesical instillation.
number: 8
text: The composition for use according to any one of the preceding claims, wherein the Bacterial Ghosts are derived from Gram-negative bacteria, preferably fromE. coli , more preferably fromE .coli Nissle 1917.
number: 9
text: The composition for use according to any one of the preceding claims, wherein the Bacterial Ghosts are recombinant Bacterial Ghosts, preferably carrying one or more tumor-associated antigens.
number: 10
text: The composition for use according to any one of the preceding claims, wherein the composition is for use in the treatment of residual primary tumor and/or tumor metastasis.
number: 11
text: The composition for use according to any one of the preceding claims comprising Bacterial Ghosts obtained from bacterial cells comprising a gene encoding a lytic protein.
number: 12
text: The composition for use according to any one of the preceding claims comprising Bacterial Ghosts which have been treated with β-propiolactone.
number: 13
text: The composition for use according to any one of the preceding claims comprising 2 x 10<10> Bacterial Ghosts per kg body weight for the first dosis and 10<10> BGs/kg for the second and following doses.
number: 14
text: The composition for use according to any one of the preceding claims, wherein the cancer is selected from bladder carcinoma, breast carcinoma, colon carcinoma, colorectal carcinoma, Head and Neck Carcinoma (HNSCC), liver carcinoma, lung carcinoma, lymphoma, melanoma, mesothelioma, monocytic and myeloid leukemia, myeloma, ovarian carcinoma, pancreas carcinoma, peritoneal carcinomatosis, renal carcinoma and/or non-melanoma skin carcinoma.
number: 15
text: The composition for use according to any one of the preceding claims,
wherein the composition is consisting of
Office action: search_report, dated 2017-07-26
Rejection reasons: novelty_epc_54
inventive_step_epc_56
Prior art cited: ref_id: US2008031900A1
ref_type: patent
severity: background
ref_id: EP2591798A1
ref_type: patent
severity: background
ref_id: WO2015035606A1
ref_type: patent
severity: background
ref_id: WO2016000619A1
ref_type: patent
severity: background
ref_id: US7968323B2
ref_type: patent
severity: background
ref_id: WO03006630A2
ref_type: patent
severity: background
ref_id: EP2009000272W
ref_type: patent
severity: background
ref_id: EP9804723W
ref_type: patent
severity: background
ref_id: EP0001906W
ref_type: patent
severity: background
ref_id: EP0100906W
ref_type: patent
severity: background
ref_id: - IARC, WHO/IARC WORLD CANCER REPORT, 2014
ref_type: npl
severity: background
ref_id: - RILEY, IMMUNOL REV, vol. 229, 2009, pages 114 - 125
ref_type: npl
severity: background
ref_id: - VIBHARKA ET AL., EXP CELL RES, vol. 232, 1997, pages 25 - 28
ref_type: npl
severity: background
ref_id: - AGATA ET AL., INT IMMUNOL, vol. 8, 1996, pages 765 - 772
ref_type: npl
severity: background
ref_id: - BENNETT ET AL., J IMMUNOL, vol. 170, 2003, pages 711 - 118
ref_type: npl
severity: background
ref_id: - BOUR-JORDAN ET AL., IMMUNOL REV, vol. 241, 2011, pages 180 - 205
ref_type: npl
severity: background
ref_id: - FREEMAN ET AL., J EXP MED, vol. 192, 2000, pages 1027
ref_type: npl
severity: background
ref_id: - EPPIHIMER ET AL., MICROCIRCULATION, vol. 9, 2002, pages 133
ref_type: npl
severity: background
ref_id: - BALD ET AL., CANCER DISCOV, vol. 4, 2014, pages 674 - 687
ref_type: npl
severity: background
ref_id: - PLANES ET AL., J VIROL, vol. 88, 2014, pages 6672 - 6689
ref_type: npl
severity: background
ref_id: - KONISHI ET AL., CLIN CANCER RES, vol. 10, 2004, pages 5094 - 5100
ref_type: npl
severity: background
ref_id: - INT J CANCER, vol. 128, 2008, pages 887 - 896
ref_type: npl
severity: background
ref_id: - GAO ET AL., CLIN CANCER RES, vol. 15, 2009, pages 971 - 979
ref_type: npl
severity: background
ref_id: - WU ET AL., ACTA HISTOCHEM, vol. 108, 2006, pages 19 - 24
ref_type: npl
severity: background
ref_id: - THOMPSON ET AL., PROC NATL ACAD SCI, vol. 101, 2004, pages 17174 - 17179
ref_type: npl
severity: background
ref_id: - THOMPSON ET AL., CLIN CANCER RES, vol. 13, 2007, pages 1757 - 1761
ref_type: npl
severity: background
ref_id: - GHEBEH ET AL., NEOPLASIA, vol. 8, 2006, pages 190 - 198
ref_type: npl
severity: background
ref_id: - HAMANISHI ET AL., PROC NATL ACAD SCI, vol. 104, 2007, pages 3360 - 3365
ref_type: npl
severity: background
ref_id: - NOMI ET AL., CLIN CANCER RES, vol. 13, 2007, pages 2151 - 2157
ref_type: npl
severity: background
ref_id: - HINO ET AL., CANCER, vol. 116, 2010, pages 1757 - 1766
ref_type: npl
severity: background
ref_id: - OHIGASHI ET AL., CLIN CANCER RES, vol. 11, 2005, pages 2947 - 2953
ref_type: npl
severity: background
ref_id: - ZHANG ET AL., BLOOD, vol. 114, 2009, pages 1545 - 1552
ref_type: npl
severity: background
ref_id: - DONG ET AL., NATURE MED, vol. 5, 1999, pages 1365
ref_type: npl
severity: background
ref_id: - TAMURA ET AL., BLOOD, vol. 97, 2001, pages 1809
ref_type: npl
severity: background
ref_id: - IWAI ET AL., PNAS, vol. 99, 2002, pages 12293
ref_type: npl
severity: background
ref_id: - BLANK ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 54, 2005, pages 307
ref_type: npl
severity: background
ref_id: - OKAZAKI ET AL., INT IMMUNOL, vol. 19, 2007, pages 813
ref_type: npl
severity: background
ref_id: - LINDAU, D.; GIELEN, P.; KROESEN, M.; WESSELING, P.; ADEMA, G.J: "The immunosuppressive tumour network: myeloidderived suppressor cells, regulatory T cells and natural killer T cells", IMMUNOLOGY, vol. 138, 2013, pages 105 - 115
ref_type: npl
severity: background
ref_id: - FLAVELL, R.A.; SANJABI, S.; WRZESINSKI, S.H.; LICONA-LIMON, P: "The polarization of immune cells in the tumour environment by TGFbeta", NAT REV IMMUNOL, vol. 10, 2010, pages 554 - 567
ref_type: npl
severity: background
ref_id: - GABRILOVICH, D.I.; OSTRAND-ROSENBERG, S; BRONTE, V: "Coordinated regulation of myeloid cells by tumours", NAT REV IMMUNOL, vol. 12, 2012, pages 253 - 268
ref_type: npl
severity: background
ref_id: - YIGIT, R.; MASSUGER, L.F.; FIGDOR, C.G.; TORENSMA, R: "Ovarian cancer creates a suppressive microenvironment to escape immune elimination", GYNECOL ONCOL, vol. 117, 2010, pages 366 - 372
ref_type: npl
severity: background
ref_id: - GABRILOVICH, D.I.; OSTRAND-ROSENBERG, S.; BRONTE, V.: "Coordinated regulation of myeloid cells by tumours", NAT REV IMMUNOL, vol. 12, 2012, pages 253 - 268
ref_type: npl
severity: background
ref_id: - SCHREIBER, R.D.; OLD, L.J.; SMYTH, M.J.: "Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion", SCIENCE, vol. 331, 2011, pages 1565 - 1570
ref_type: npl
severity: background
ref_id: US2012040829A1
ref_type: patent
severity: background
ref_id: EP2591798A1
ref_type: patent
severity: background
ref_id: - SZOSTAK M P ET AL: "Bacterial ghosts: non-living candidate vaccines", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 44, no. 1, 26 January 1996 (1996-01-26), pages 161 - 170, XP004036862, ISSN: 0168-1656, DOI: 10.1016/0168-1656(95)00123-9
ref_type: npl
severity: background
ref_id: - TIMO LANGEMANN ET AL: "The Bacterial Ghost platform system: production and applications", BIOENGINEERED BUGS, LANDES BIOSCIENCE, US, vol. 1, no. 5, 1 September 2010 (2010-09-01), pages 326 - 336, XP002672825, ISSN: 1949-1018, DOI: 10.4161/BBUG.1.5.12540
ref_type: npl
severity: background
ref_id: US2012040829
ref_type: patent
severity: novelty_destroying
ref_id: EP2591798
ref_type: patent
severity: novelty_destroying
ref_id: - SZOSTAK M P ET AL, "Bacterial ghosts: non-living candidate vaccines", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (19960126), vol. 44, no. 1, doi:10.1016/0168-1656(95)00123-9, ISSN 0168-1656, pages 161 - 170, XP004036862 [Y] 1-15 * the whole document *
ref_type: npl
severity: obviousness
ref_id: - TIMO LANGEMANN ET AL, "The Bacterial Ghost platform system: production and applications", BIOENGINEERED BUGS, LANDES BIOSCIENCE, US, (20100901), vol. 1, no. 5, doi:10.4161/BBUG.1.5.12540, ISSN 1949-1018, pages 326 - 336, XP002672825 [Y] 1-15 * the whole document *
ref_type: npl
severity: obviousness
Final disposition: pending (2017-07-26)